C57BL/6 α-1,3-Galactosyltransferase knockout mouse as an animal model for experimental Chagas disease

Ynocente Lavalle, Raúl Jesus; Rodrigues da Cunha, Gisele; Calderón Sánchez, Maritza Mercedes; Valencia Ayala, Edward; Gazzinelli, Ricardo; Venuto, Ana Paula; Hincapie, Robert; Finn, M. G.; Jimenez, Juan; Marques, Alexandre F.; Vidal Riva, Angela Giovana; Araujo Azevedo, Maira

dc.contributor.author	Valencia Ayala, Edward
dc.contributor.author	Rodrigues da Cunha, Gisele
dc.contributor.author	Araujo Azevedo, Maira
dc.contributor.author	Calderón Sánchez, Maritza Mercedes
dc.contributor.author	Jimenez, Juan
dc.contributor.author	Venuto, Ana Paula
dc.contributor.author	Gazzinelli, Ricardo
dc.contributor.author	Ynocente Lavalle, Raúl Jesus
dc.contributor.author	Vidal Riva, Angela Giovana
dc.contributor.author	Hincapie, Robert
dc.contributor.author	Finn, M. G.
dc.contributor.author	Marques, Alexandre F.
dc.date.accessioned	2020-07-14T00:02:36Z
dc.date.available	2020-07-14T00:02:36Z
dc.date.issued	2020
dc.identifier.uri	https://hdl.handle.net/20.500.12866/8355
dc.description.abstract	The leading animal model of experimental Chagas disease, the mouse, plays a significant role in studies for vaccine development, diagnosis, and human therapies. Humans, along with Old World primates, alone among mammals, cannot make the terminal carbohydrate linkage of the α-Gal trisaccharide. It has been established that the anti-α-Gal immune response is likely to be a critical factor for protection against Trypanosoma cruzi (T. cruzi) infection in humans. However, the mice customarily employed for the study of T. cruzi infection naturally express the α-Gal epitope and therefore do not produce anti-α-Gal antibodies. Here, we used the C57BL/6 α-1,3-galactosyltransferase knockout (α-GalT-KO) mouse, which does not express the α-Gal epitope as a model for experimental Chagas disease. We found the anti-α-Gal IgG antibody response to an increase in α-GalT-KO mice infected with Arequipa and Colombiana strains of T. cruzi, leading to fewer parasite nests, lower parasitemia, and an increase of INF-γ, TNF-α, and IL-12 cytokines in the heart of α-GalT-KO mice compared with α-GalT-WT mice on days 60 and 120 postinfection. We therefore agree that the C57BL/6 α-GalT-KO mouse represents a useful model for initial testing of therapeutic and immunological approaches against different strains of T. cruzi.	en_US
dc.language.iso	eng
dc.publisher	American Chemical Society
dc.relation.ispartofseries	ACS Infectious Diseases
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	Chagas disease	en_US
dc.subject	mouse model	en_US
dc.subject	Trypanosoma cruzi	en_US
dc.subject	α-Gal	en_US
dc.subject	α-Gal antibodies	en_US
dc.subject	α-Gal knockout mouse	en_US
dc.title	C57BL/6 α-1,3-Galactosyltransferase knockout mouse as an animal model for experimental Chagas disease	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1021/acsinfecdis.0c00061
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn	2373-8227